Severe early-onset fetal growth restriction (FGR) predisposes to fetal death, neonatal death, neonatal morbidity and neurodisability. The use of placental biomarkers has been proposed for risk stratification in pre-eclampsia, but they could be equally useful in fetal growth restriction in aiding management.
To determine the efficacy of angiogenic biomarkers at predicting adverse pregnancy outcome in severe early-onset fetal growth restriction.
This is a secondary analysis of the multicentre, placebo-controlled STRIDER UK randomised controlled trial of singleton pregnancies with severe early-onset fetal growth restriction.
Women with FGR pregnancies between 22+0 and 29+6 weeks of gestation were randomly assigned to receive either sildenafil 25 mg three times daily or placebo until 32+0 weeks’ gestation or delivery. We developed prediction models based upon maternal demographics (age, parity, blood pressure, preeclampsia, gestational hypertension), fetal biometric (estimated fetal weight) and Doppler measurements (Middle Cerebral Artery (MCA), Umbilical Artery (UA)) and maternal angiogenic biomarkers [placental growth factor (PlGF), soluble endoglin (sEng), soluble fms-like tyrosine kinase 1 (sFlt-1) and sFlt-1:PlGF ratio) using both univariate and multivariate analysis.
A complete data set was available for 105 of 135 randomised women. Multivariate regression analysis identified estimated fetal weight (EFW) and sFlt-1:PlGF as independent predictors of livebirth (EFW OR: 1.01 (1.008, 1.021); p < 0.001 and lower sFlt-1:PlGF ratio OR: 0.53 (0.284, 0.994); p = 0.048) and overall survival (EFW OR: 1.01 (1.006, 1.015); p < 0.001 and lower sFlt-1/PlGF ratio OR: 0.51 (0.286, 0.904); p = 0.021). EFW was a consistent predictor for all outcomes other than gestation at delivery. sFlt-1:PlGF ratio was a consistent predictor for all outcomes other than neonatal morbidity.
In severe early-onset FGR pregnancies livebirth and overall survival can be predicted using a model involving EFW and sFlt-1:PlGF ratio. This model require validation in a larger cohort but may allow informed decision making about pregnancy management, especially in previable cases.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Obstetrics and Gynecology and Reproductive Biology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Short-term outcome of periviable small-for-gestational-age babies: is our counseling up to date?.Ultrasound Obstet Gynecol. 2016; 48: 636-641
- Predictors of neonatal outcome in early-onset placental dysfunction.Obstet Gynecol. 2007; 109: 253-261
- Early second-trimester fetal growth restriction and adverse perinatal outcomes.Obstet Gynecol. 2017; 130: 865-869
- Intellectual and psychological perfromance in males born small for gestational age with and without catch-up growth.Pediatr Res. 2001; 50: 91-96
- Outcome at 5 years of age of SGA and AGA infants born less than 28 weeks of gestation.Semin Perinatol. 2004; 28: 288-294
- Growth and neurodevelopmental outcome of very low birth weight infants with intrauterine growth retardation: comparison with control subjects matched by birth weight and gestational age.J Pediatr. 1993; 123: 618-624
- 2 year neurodevelopmental and intermediate perinatal outcomes in infants with very preterm fetal growth restriction (TRUFFLE): a randomised trial.Lancet. 2015; 385: 2162-2172
- Amplitude of pubertal growth in short stature children with intrauterine growth retardation.Horm Res. 2002; 57: 88-94
- Fetal growth and coronary heart disease in south india.Lancet. 1996; 348: 1269-1273
- The developmental origins of chronic adult disease.Acta Paediatr Suppl. 2004; 93: 26-33
- Perinatal morbidity and mortality in early-onset fetal growth restriction: cohort outcomes of the trial of randomized umbilical and fetal flow in Europe (TRUFFLE).Ultrasound Obstet Gynecol. 2013; 42: 400-408
- Expression, distribution and regulation of phosphodiesterase 5.Curr Pharm Des. 2006; 12: 3439-3457
- Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial.Lancet Child Adolesc Health. 2018; 2: 93-102
- Predicting delivery of a small-for-gestational-age infant and adverse perinatal outcome in women with suspected pre-eclampsia.Ultrasound Obstet Gynecol. 2018; 51: 387-395
- Predictors of poor perinatal outcome following maternal perception of reduced fetal movements—a prospective cohort study.PLoS One. 2012; 7: e39784
- Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction.Placenta. 2016; 42: 1-8
- Placental Growth Factor informed management of suspected pre-eclampsia or fetal growth restriction: the MAPPLE cohort study.Pregnancy Hypertens. 2018;
- The prediction of fetal death with a simple maternal blood test at 20–24 weeks: a role for angiogenic index-1 (PlGF/sVEGFR-1 ratio).Am J Obstet Gynecol. 2017; 217 (e1- e13): 682
- Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia.Am J Obstet Gynecol. 2013; 208 (e1- e15): 287
- Screening for fetal growth restriction with universal third trimester ultrasonography in nulliparous women in the Pregnancy Outcome Prediction (POP) study: a prospective cohort study.Lancet. 2015;
- Screening for fetal growth restriction using ultrasound and the sFLT1/PlGF ratio in nulliparous women: a prospective cohort study.Lancet Child Adolesc Health. 2018; 2: 569-581
- Longitudinal change of sFlt-1/PlGF ratio in singleton pregnancy with early-onset fetal growth restriction.Ultrasound Obstet Gynecol. 2018; 52: 631-638
- Association between the high soluble fms-like tyrosine kinase-1 to placental growth factor ratio and adverse outcomes in asymptomatic women with early-onset fetal growth restriction.Hypertens Pregnancy. 2017; 36: 269-275
- Diagnostic accuracy of placental growth factor in women with suspected preeclampia: a prospective multicenter study.Circulation. 2013; 128: 2121-2131
- Evaluation of agreement of placental growth factor (PlGF) tests and the soluble FMS-like tyrosine kinase 1 (sFlt-1)/PlGF ratio, comparison of predictive accuracy for pre-eclampsia, and relation to uterine artery Doppler and response to aspirin.J Matern Fetal Neonatal Med. 2017; : 1-9
- A low angiogenic index-1 (PlGF/sVEGFR-1 ratio) at 24–28 weeks of gestation is a biomarker to identify the patient at risk for subsequent fetal death.Am J Obstet Gynecol. 2017;
- Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia.N Engl J Med. 2016; 374: 13-22
- Performance of third-trimester combined screening model for prediction of adverse perinatal outcome.Ultrasound Obstet Gynecol. 2017; 50: 353-360
- A comparison of Doppler and biophysical findings between liveborn and stillborn growth-restricted fetuses.Am J Obstet Gynecol. 2014; 211 (669 e1-e10)
- Stage-based approach to the management of fetal growth restriction.Prenat Diagn. 2014; 34: 655-659
- Fetal brain Doppler to predict cesarean delivery for nonreassuring fetal status in term small-for-gestational-age fetuses.Obstet Gynecol. 2011; 117: 618-626
- Fetal cerebral blood flow redistribution in late gestation: identification of compromise in small fetuses with normal umbilical artery Doppler.Ultrasound Obstet Gynecol. 2000; 15: 209-212
- The role of brain sparing in the prediction of adverse outcomes in intrauterine growth restriction: results of the multicenter PORTO Study.Am J Obstet Gynecol. 2014; 211 (e1-5): 288
- Diagnostic accuaracy of biochemical tests of placental function versus ultrasound assessment of fetal size for stillbirth and small-for-gestational-age infants (Protocol).Cochrane Database Syst Rev. 2016; (No.: CD012245)
- The investigation and management of the small-for-gestational-age fetus. Green-top guideline No31.2013
Published online: August 16, 2019
Accepted: August 15, 2019
Received in revised form: August 11, 2019
Received: February 12, 2019
© 2019 Published by Elsevier B.V.